Shilpa Medicare Ltd’s Unit IV (Jadcherla, Telangana) completed a 10-day US FDA inspection ending 21 Nov 2025 and received a Form 483 citing eight non-repeat observations; US sales from this plant were under 1% in H1 FY26 and under 5% in FY24-25.
Source: Shilpa Medicare Limited Press Release (NSE Exchange Fillings) | Published on Nov 22, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release of Shilpa Medicare Limited (NSE Exchange Filings), the company revealed that its manufacturing facility, Unit IV, located at Jadcherla in Telangana, India, was subjected to a ten-day inspection from the U.S. Food and Drug Administration (US FDA), which was completed on 21 November 2025. The inspection concluded with a Form 483 containing eight inspectional observations, none of which were identified as repeat observations. The facility is authorised for the manufacture, packaging, testing, storage and/or distribution of sterile injectable products as well as oral tablets and capsules.
The company noted that U.S. sales of products manufactured at this facility accounted for less than 1% of total sales in the first half of FY25-26, and less than 5% of total sales in FY24-25. The facility received approvals from regulators in addition to US FDA, which includes the European Medicines Agency (EMA), Health Canada, Anvisa (Brazil) and the Therapeutic Goods Administration (TGA) of Australia. The company further mentioned that it will respond to the observations within the required timeframe.
Also read: Lupin Gets US FDA Form-483 With Seven Observations at the Goa Unit
Inspection period: 10 days, ending 21 November 2025.
Facility: Unit IV, Jadcherla, Telangana.
Outcome: Form 483 with eight non-repeat observations.
U.S. sales from plant: <1% of total in H1 FY26; <5% of total in FY24-25.
Facility approvals: EMA, Health Canada, Anvisa, TGA.
Also read: Tata Chemicals Approves ₹910 Crore Plant Expansions at Mithapur & Cuddalore
Item | Details |
Plant location | Unit IV, Jadcherla, Telangana |
Inspection authority | U.S. Food and Drug Administration |
Inspection duration | 10 days |
Form 483 observations | Eight |
Repeat observations | None |
U.S. sales contribution (H1 FY26) | Less than 1% |
U.S. sales contribution (FY24-25) | Less than 5% |
Regulatory approvals held | EMA, Health Canada, Anvisa (Brazil), TGA (Australia) |
The inspection and findings invite questions with respect to operational controls in the facility. At the same time, although the unit is approved by multiple global regulators the issuance of eight observations by US FDA indicates there are areas that require remediation. In supporting a plant supplying to established markets with sterile injectables and oral dosage forms, compliance with current Good Manufacturing Practice (CGMP) requirements is imperative. Even if the contribution of U.S.-market sales from this unit is small (less than 1% in H1 FY26 and less than 5% in FY24-25), the outcome of the inspection may materially impact media production, regulatory submissions for market access for this facility.
Shilpa Medicare Limited share price stands at ₹350.60 per share on the BSE as of 21 November 2025 at 15:30 PM IST, down by 1.60%.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading